Elevance Health, Inc. $ELV Shares Sold by Iridian Asset Management LLC CT
by Kim Johansen · The Markets DailyIridian Asset Management LLC CT trimmed its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 51.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,074 shares of the company’s stock after selling 27,029 shares during the period. Elevance Health makes up about 3.2% of Iridian Asset Management LLC CT’s portfolio, making the stock its 11th largest holding. Iridian Asset Management LLC CT’s holdings in Elevance Health were worth $8,790,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Elevance Health in the fourth quarter valued at $5,941,000. Evergreen Wealth Management LLC increased its holdings in shares of Elevance Health by 33.5% in the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock valued at $5,584,000 after buying an additional 4,336 shares in the last quarter. Blume Capital Management Inc. increased its holdings in shares of Elevance Health by 236.7% in the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after buying an additional 4,320 shares in the last quarter. Canoe Financial LP increased its holdings in shares of Elevance Health by 18.1% in the third quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock valued at $125,823,000 after buying an additional 59,743 shares in the last quarter. Finally, Synergy Asset Management LLC increased its holdings in shares of Elevance Health by 100.0% in the third quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock valued at $33,712,000 after buying an additional 52,167 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.
Elevance Health Price Performance
Shares of NYSE:ELV opened at $311.54 on Monday. The company’s fifty day moving average is $311.25 and its two-hundred day moving average is $332.13. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $443.29. The company has a market cap of $68.43 billion, a P/E ratio of 12.40, a price-to-earnings-growth ratio of 1.71 and a beta of 0.49.
Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the previous year, the business earned $3.84 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.
Elevance Health Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.72 per share. The ex-dividend date was Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.2%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.39%.
Analyst Ratings Changes
Several research firms have issued reports on ELV. Mizuho dropped their price target on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. Jefferies Financial Group dropped their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Leerink Partners upped their price target on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a report on Tuesday, February 3rd. Finally, Weiss Ratings cut Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $385.38.
Read Our Latest Analysis on Elevance Health
About Elevance Health
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.